Clinical trial NCT00933543: Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
Official title: A Double Blinded, Prospective, Randomized, Stratified, Placebo-controlled, Multi-center Study of Photodynamic Therapy With VisonacTM Cream in Patients With Moderate to Severe Acne Vulgaris.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acne Vulgaris
Keywords: Acne Vulgaris
Moderate to severe
Lead sponsor: Photocure
Sponsor class: INDUSTRY
First posted: 2009-07-07
Enrollment: 107
Sex: ALL
Minimum age (years): 9
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from 9 to 35 years old with Aktilite® CL512. Patients was randomized to Visonac or vehicle cream without occlusion and red light(dose: 37J/cm2)

Detailed description: Double blinded, prospective, randomized, stratified, placebo-controlled, multi-center study in patients with moderate to severe acne vulgaris. Patients with facial severity grades 3 to 4 on the Investigator's Global Assessment (IGA) scale will be included. Each patient will be classified according to age in the two age groups 9 to 12 years and 13 to 35 years and randomized to either Visonac or vehicle cream within each age group. All patients will receive 4 treatments 2 weeks apart (at week 0, 2 ,4 and 6 week). Efficacy evaluation will be done after each treatment and at 12 weeks after the first treatment. Safety evaluations will be performed at each treatment visit and at 12 weeks after the first treatment.

Photographs of patients will be taken before and after treatment at first and last treatment visit, and at 12 weeks after first treatment.

Blood samples will be drawn at 3 visits; pre-treatment visit, one week after first treatment and at one week after last treatment visit.

Eligibility criteria: Inclusion Criteria:

* Female and male patients, above 9 years of age with moderate to severe facial acne vulgaris (IGA score 3-4).
* Female patients who are surgically sterile, pre-menstrual, postmenopausal, abstinent, or willing to use an adequate means of contraception including birth control pills, or barrier methods and spermicide for at least 14 days prior to T1. Patients using birth control pills must have used the same product and dose for at least 6 months and must agree to stay with the same product and dose for an additional 6 months.
* Fitzpatrick skin type I through VI.
* Patients with 20 to 100 inflammatory lesions (papules, pustules, and nodules) on the face.
* Patients with 30 to 120 non-inflammatory lesions (open and closed comedones) on the face.
* Patients with no more than 2 nodular lesions on the face.
* Signed and verified informed consent form. For subjects under age of 18, an assent form in conjunction with an informed consent form, signed and verified by parent/guardian.

Exclusion Criteria:

Patients presenting with any of the following will not be included in the study:

* Patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
* Patients unlikely to comply with the protocol, e.g., mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the clinical study, uncooperative attitude or unlikelihood of completing the study (e.g., drug or alcohol abuse).
* Female patients using oral contraceptives, that have not used the same product or dose within the last 6 months and do not agree to stay with the same product and dose for the duration of the study.
* Pregnancy
* Patients undergoing testosterone or any other systemic hormonal treatment.
* Patients using hormonal contraceptives solely for the control of acne.
* Known allergy to MAL, to a similar PDT compound, or to excipients of the cream.
* Patients with porphyria.
* Patients with cutaneous photosensitivity.
* Participation in other clinical studies either concurrently or within the last 30 days, before T1.
* Patients with a washout period for topical treatments e.g., topical BPOs, retinoids and antibiotics, for their acne of less than 14 days, before T1. Medicated cleansers may be used during the washout period and stopped before the treatment.
* Patients with a washout period for oral antibiotics for treatment of their acne of less than 1 month, before T1.
* Patients with a washout period for oral isotretinoin of less than 6 months, before T1.
* Patients with a beard or other facial hair that might interfere with study assessments.
* Patients with melanoma or dysplastic nevi in the treatment area.
* Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within the last 30 days.
* Exposure to PDT within 12 weeks before T1.

Primary outcomes:
measure: Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.
timeFrame: 12 weeks after the first treatment
measure: Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules)
timeFrame: 12 weeks after the first treatment
measure: Absolute Change From Baseline in Facial Non Inflammatory Lesion Count
timeFrame: 12 weeks after first treatment
Secondary outcomes:
measure: Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count
timeFrame: 6 weeks after the first treatment
measure: Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count
timeFrame: 12 weeks after the first treatment
measure: Percent Change From Baseline in Facial Non Inflammatory Lesion Count
timeFrame: 6 weeks after first treatment
measure: Percent Change From Baseline in Facial Non Inflammatory Lesion Count
timeFrame: 12 weeks after first treatment
measure: Percent Change From Baseline in Facial Total Lesion Count
timeFrame: 6 weeks after the first treatment
measure: Percent Change From Baseline in Facial Total Lesion Count
timeFrame: 12 weeks after the first treatment
measure: Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Non-inflammatory Lesion Count
timeFrame: 12 weeks after last treatment
measure: Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Inflammatory Lesion Count From Baseline
timeFrame: 12 weeks after first treatment
measure: Absolute Change From Baseline in Facial Inflammatory Lesion Count
timeFrame: 6 weeks after the first treatment
measure: Absolute Change From Baseline in Facial Non- Inflammatory Lesion Count
timeFrame: 6 weeks after the first treatment
measure: Absolute Change From Baseline in Facial Total Lesion Count
timeFrame: 6 weeks after the first treatment
measure: Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.
timeFrame: 6 weeks after the first treatment
measure: Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable
timeFrame: directly after first treatment
measure: Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable
timeFrame: directly after second treatment
measure: Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable
timeFrame: directly after third treatment
measure: Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable
timeFrame: directly after fourth treatment
measure: Proportion of Patients With Mild and Moderate Hyperpigmentation
timeFrame: at 12 weeks after first treatment
measure: Proportion of Patients With Severe Hyperpigmentation
timeFrame: at 12 weeks after first treatment
measure: Proportion of Patients With Mild or Moderate Scarring at End of Study
timeFrame: week 12
measure: Proportion of Patients With Clear or Almost Clear Scarring at End of Study
timeFrame: week 12
measure: Proportion of Patients With Severe and Very Severe Scarring at End of Study
timeFrame: week 12
measure: Proportion of Patients With Hypopigmentation (Mild Moderate, Severe)
timeFrame: at 12 weeks after first treatment
measure: Proportion of Patients With Dryness (Mild)
timeFrame: at 12 weeks after first treatment
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Children's Specialists of San Diego / Rady Children's Hospital San Diego
state: California
city: Chicago
country: United States
facility: DeNova Research
state: Illinois
city: Naperville
country: United States
facility: Dermatology Institute of DuPage Medical Group
state: Illinois
city: Fridley
country: United States
facility: Minnesota Clinical Study Center
state: Minnesota
city: Rochester
country: United States
facility: Dermatology Associates of Rochester
state: New York
city: Hershey
country: United States
facility: Milton S. Hershey Medical Center
state: Pennsylvania
city: Norfolk
country: United States
facility: Virginia Clinical Research, Inc.
state: Virginia
city: Madison
country: United States
facility: Madison Skin & Research, Inc
state: Wisconsin
city: Windsor, Ontario N8W 5L7
country: Canada
facility: Windsor Clinical Research, Inc.
state: Ontario
city: Montreal
country: Canada
facility: INNOVADERM Research Inc.
state: Quebec
city: Québec
country: Canada
facility: Centre de Recherche Dermatologique
state: Quebec
Study officials:
affiliation: Children's Specialists of San Diego / Rady Children's Hospital San Diego
name: Lawrence F. Eichenfield, M.D
role: PRINCIPAL_INVESTIGATOR
References: